PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Abstract BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the promotion of precancerous lesions and secondary n...

Full description

Bibliographic Details
Main Authors: Candani S. A. Tutuka, Miles C. Andrews, John M. Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, Andreas Behren
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Molecular Cancer
Subjects:
BRAF
Melanoma
Colorectal cancer
Paradoxical activation
MAPK pathway
Online Access:http://link.springer.com/article/10.1186/s12943-017-0684-x

Internet

http://link.springer.com/article/10.1186/s12943-017-0684-x

Similar Items